Evidence map›Paper›PMID 19210794›Full record

ArticleBMC microbiology2009

Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors.

Sara E Jones, James Versalovic

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04847960 (The Effect of Probiotic Lactobacillus Reuteri Prodentis Consumption on Gingival Crevicular Fluid Inflammatory Response and Metagenomic Profiles of Oral Microbiome in Orthodontic Patients.), which is not on this map. Cited by 193 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 4 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04847960 naunknown statusnot on this mapstarted 2021, after this paper: background citation

The Effect of Probiotic Lactobacillus Reuteri Prodentis Consumption on Gingival Crevicular Fluid Inflammatory Response and Metagenomic Profiles of Oral Microbiome in Orthodontic Patients.

TypeinterventionalSponsorTrisakti UniversityRan2021 to 2023Enrolled20ConditionsHealthy Subjects With Fixed OrthodonticsArmsBioGaia Probiotic Lozenges
3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 4 syntheses or guidelines pooled it, 413 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Effects of Low-Energy Diets Supplemented withAnimals : an open access journal from MDPI · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sara E JonesDepartment of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA. saraj@bcm.edu
James Versalovic
Baylor College of Medicine · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
Intestinal Lactobacillus and Mucosal ImmunomodulationR01DK065075 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2007 to 2010
$1.3M
Probiotic Lactobacillus-Mediated Suppression of TNF in Pediatric Crohn's DiseaseR21AT003482 · NCCIH · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2007 to 2008
$408k
NCCIH NIH HHS AT003482NIDDK NIH HHS DK065075NIDDK NIH HHS DK56338
6 · The paper itself

Abstract

backgroundCommensal-derived probiotic bacteria inhibit enteric pathogens and regulate host immune responses in the gastrointestinal tract, but studies examining specific functions of beneficial microbes in the context of biofilms have been limited in scope.

resultsLactobacillus reuteri formed biofilms that retained functions potentially advantageous to the host including modulation of cytokine output and the production of the antimicrobial agent, reuterin. Immunomodulatory activities of biofilms were demonstrated by the abilities of specific L. reuteri strains to suppress human TNF production by LPS-activated monocytoid cells. Quantification of the antimicrobial glycerol derivative, reuterin, was assessed in order to document the antipathogenic potential of probiotic biofilms. L. reuteri biofilms differed in the quantities of reuterin secreted in this physiological state.

conclusionL. reuteri biofilms secreted factors that confer specific health benefits such as immunomodulation and pathogen inhibition. Future probiotic selection strategies should consider a strain's ability to perform beneficial functions as a biofilm.

Indexed as

BiofilmsAnti-Infective AgentsAnti-Inflammatory AgentsCell LineGlyceraldehydeHumansLimosilactobacillus reuteriProbioticsPropaneTumor Necrosis Factor-alpha3-hydroxypropionaldehydeAnti-Infective AgentsAnti-Inflammatory AgentsGlyceraldehydePropaneTumor Necrosis Factor-alpha

Identifiers

PMID19210794
PMCPMC2653509
OpenAlexW2089612575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.